Trending News

Cell and gene therapies
#Diabetes #Fractyl Health #Gene therapy #GLP-1 #Phase I trial

First GLP-1 gene therapy gets green light for diabetes trial

Fractyl Health has received Clinical Trial Application authorisation in the Netherlands to initiate the Phase I/II first-in-human study of RJVA-001, the first clinical candidate from the company’s Rejuva Smart GLP-1 gene therapy platform.   With this authorisation, Fractyl believes RJVA-001 is the first adeno-associated virus (AAV)-based gene therapy… Read More

#News #Trending News

#CellCentric #Fundraising #Oncology #T cell engagers

CellCentric raises $220m to advance trials of oral myeloma drug

CellCentric has completed an oversubscribed $220 million Series D financing led by Venrock Healthcare Capital Partners, with participation from new and existing investors.  The proceeds will support clinical trials for multiple myeloma therapy inobrodib. These will include continued enrolment of the company’s Phase II DOMMINO-1 study and initiation of the… Read More

#Business & Investment #News #Trending News

FDA headquarters
#Clinical trial design #Clinical trials #FDA #Real-time clinical trials

FDA moves towards real-time clinical trials

The US Food and Drug Administration has announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).   First, the agency unveiled the successful initiation of two proof-of-concept clinical trials that will report endpoints and data signals to the agency in real time. Read More

#Editor's Choice #News #Regulatory #Trending News

Gene therapy
#FDA #Gene therapy #Hearing Loss #Regeneron Pharmaceuticals

FDA approves first gene therapy for genetic hearing loss

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Otarmeni (lunsotogene parvec-cwha), the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher programme.   Otarmeni is an adeno-associated virus vector-based gene therapy indicated for the treatment of paediatric and… Read More

#News #Regulatory #Trending News

Ovarian cancer
#Corcept Therapeutics #Oncology #Ovarian cancer #Phase III trial

Combo treatment new SOC in platinum-resistant ovarian cancer

Corcept Therapeutics has shared final overall survival data from its pivotal Phase III ROSELLA trial of Lifyorli (relacorilant) combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-resistant ovarian cancer.  The results were shared in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) 2026… Read More

#Cancer Research #News #Trending News

Pills
#Eli Lilly #FDA #GLP-1 #Obesity #Weight loss

FDA approves Lilly’s GLP-1 pill for weight loss

The US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.   "People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water… Read More

#News #Regulatory #Trending News

Cell and gene therapy
#FDA #Gene therapy #Paediatrics #Rare disease #Rocket Pharmaceuticals

First gene therapy for rare paediatric disease gets US approval

The US Food and Drug Administration (FDA) has granted accelerated approval for Kresladi (marnetegragene autotemcel), an autologous haematopoietic stem cell-based gene therapy.  It is indicated for the treatment of paediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling… Read More

#News #Regulatory #Trending News

Professor Stephen Wallace harvesting engineered bacteria for analysis.
#Bacteria #Neuroscience #Parkinson's #University of Edinburgh

Edinburgh team makes Parkinson’s drugs from plastic bottles

A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows.  The approach harnesses bacteria to transform post-consumer plastic into L-DOPA, a frontline medication for the neurological disorder.  It is the first time a natural, biological… Read More

#News #Trending News

Novo Nordisk head office
#Adverse event #FDA #GLP-1 #Novo Nordisk #Obesity #Ozempic

Novo receives FDA warning, strikes deal with Hims & Hers

Novo Nordisk has received a Warning Letter from the US Food and Drug Administration (FDA) related to violations of postmarketing adverse drug experience (PADE) regulations.  The letter relates to an inspection that took place in early 2025, in which the FDA found serious violations of PADE reporting requirements, in response… Read More

#Business & Investment #News #Regulatory #Trending News

#Advanced Therapies #FDA #Gene therapy #Huntington's disease #uniQure

Investors file lawsuit against uniQure following FDA ruling

The US Food and Drug Administration (FDA) has ruled that data from Phase I/II studies are insufficient evidence to approve the marketing authorisation for uniQure’s AMT-130, an investigational gene therapy for Huntington’s disease (HD).   In response, investors have issued a class action securities lawsuit to recover losses.  The FDA said… Read More

#Business & Investment #News #Trending News

CRISPR gene editing
#Advanced Therapies #FDA #Gene therapy #Intellia Therapeutics #Phase III trial

Regulator lifts clinical hold on Intellia’s gene therapy trials

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase III clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).  The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed… Read More

#News #Regulatory #Trending News

Scales showing a comparison between Mounjaro and Ozempic
#GLP-1 #Novo Nordisk #Obesity #Weight loss

Head-to-head obesity trial disappointment for Novo Nordisk 

Novo Nordisk has seen a significant fall in its stock value following disappointing trial results for its obesity treatment CagriSema, which is a fixed dose combination of cagrilintide 2.4mg and semaglutide 2.4mg.  Although CagriSema demonstrated 23% weight loss in the open-label head-to-head Phase III REDEFINE 4 trial,… Read More

#News #Trending News

Gilead offices
#Advanced Therapies #Arcellx #CAR-T #Cell therapy #Gilead Sciences #Mergers and acquisitions

Gilead Sciences to acquire CAR-T company Arcellx

Gilead Sciences has entered into a definitive agreement to acquire Arcellx for an equity value of $7.8 billion.   Arcellx is a biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases.  The companies have an existing collaboration to co-develop and co-commercialise Arcellx’s… Read More

#Business & Investment #News #Trending News

Sanofi offices
#New appointment #Sanofi

Merck’s Belén Garijo takes over at Sanofi

Sanofi's Board of Directors has decided not to renew the Paul Hudson’s contract as CEO and to replace him with current Merck CEO Belén Garijo.  They have announced that Olivier Charmeil, Executive Vice President, General Medicines, will assume the role of Interim Chief Executive Officer during the transition.  Garijo has… Read More

#Business & Investment #News #Trending News

CAR-T cells attacking a cancer cell
#Advanced Therapies #CAR-T #Cell therapy #Lyell Immunopharma #Lymphoma #Oncology #Phase III trial

CAR-Ts go head-to-head in first-of-its-kind clinical trial

Lyell Immunopharma has begun its PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtageneciloleucel (axi-cel).  The CAR-T therapies will be assessed in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line… Read More

#Cancer Research #News #Trending News

REGENXBIO
#Advanced Therapies #Adverse event #FDA #Gene therapy #Hunter Syndrome #Phase I trial #REGENXBIO

FDA pauses REGENXBIO’s gene therapies following tumour discovery

The US Food and Drug Administration (FDA) has placed a clinical hold on REGENXBIO’s investigational gene therapy, RGX-111, for the treatment of MPS I, following a single case of neoplasm (intraventricular CNS tumour) in a participant treated in its Phase I/II study.  The FDA also placed a clinical hold on… Read More

#News #Regulatory #Trending News